Amarin Corp. PLC (NASDAQ:AMRN) shares were down 7.6% during mid-day trading on Monday . The stock traded as low as $2.79 and last traded at $2.93, with a volume of 4,973,203 shares traded. The stock had previously closed at $3.17.
Several research analysts have recently issued reports on AMRN shares. Zacks Investment Research raised Amarin Corp. PLC from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a research note on Thursday, August 4th. Jefferies Group reissued a “buy” rating on shares of Amarin Corp. PLC in a research note on Tuesday, May 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Amarin Corp. PLC in a research note on Monday, August 8th.
The stock’s market capitalization is $544.43 million. The firm’s 50-day moving average is $2.95 and its 200 day moving average is $2.10.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Amarin Corp. PLC (NASDAQ:AMRN) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. The firm had revenue of $32.82 million for the quarter, compared to analyst estimates of $29.97 million. During the same period in the previous year, the business posted ($0.15) EPS. Amarin Corp. PLC’s revenue for the quarter was up 85.4% compared to the same quarter last year. Equities analysts forecast that Amarin Corp. PLC will post ($0.46) EPS for the current fiscal year.
Amarin Corp. PLC Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Corp. PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amarin Corp. PLC and related companies with’s FREE daily email newsletter.